Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2349664 | 0.83 | HTR2A (0.31) | HTR2AHTR2CHTR2B | |
| SCHEMBL158430 | 0.80 | HTR2A (0.30) | HTR2AHTR2CHTR2B | |
| SCHEMBL1028624 | 0.80 | GAA (0.31) | NPC1TAAR1HTR2AHTR2CHTR2B | |
| SCHEMBL15352895 | 0.79 | CSNK2A1 (0.31) | — | |
| SCHEMBL15352890 | 0.79 | LMNA (0.32) | HTTALDH1A1 | |
| SCHEMBL219318 | 0.77 | GAA (0.42) | MAPTNPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL7255898 | 0.77 | ACHE (0.33) | MAPTHTTRAB9AALDH1A1HTR2A | |
| SCHEMBL1526163 | 0.77 | KDM4E (0.33) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6683483 | 0.75 | CA2 (0.34) | — | |
| SCHEMBL617825 | 0.75 | MAPT (0.34) | MAPTHTTRAB9AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021078120-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-29 | — | — | WO | disclosed |
| EP-2841429-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2020-10-21 | — | — | EP | disclosed |
| US-10077254-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-09-18 | — | — | US | disclosed |
| EP-3059233-B1 | TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME | SUMITOMO CHEMICAL CO (JP) | 2017-12-20 | — | — | EP | disclosed |
| US-9565856-B2 | Tetrazolinone compounds and its use as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-14 | — | — | US | disclosed |
| US-20160272622-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-09-22 | — | — | US | disclosed |
| EP-3059233-A1 | TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME | Sumitomo Chemical Company, Limited (JP) | 2016-08-24 | — | — | EP | disclosed |
| EP-2841429-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | Sumitomo Chemical Company Limited (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-20150051171-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-02-19 | — | — | US | disclosed |
| WO-2013162072-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-10-31 | — | — | WO | disclosed |
| US-8008232-B2 | Such as N-(3',4'-dichlorobiphenyl-2-yl)-5-chloro-1,3-dimethyl-1H-pyrazole-4-carboxamide; seeds | BASF AKTIENGESELLSCHAFT (DE) | 2011-08-30 | — | — | US | disclosed |
| US-20080153707-A1 | Pyrazolecarboxanilides, Process for Their Preparation and Compositions Comprising Them for Controlling Harmful Fungi | BASF AKITENGESELLSCHAFT (DE) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153707-A1 | Pyrazolecarboxanilides, Process for Their Preparation and Compositions Comprising Them for Controlling Harmful Fungi | CBR3, C1S, PYM1 | MAPT 4417/4885NPC1 1969/4885HTT 3205/4885 |
| US-10077254-B2 | Tetrazolinone compound and use thereof | MT-CO1, UQCRB, MT-CO2 | MAPT 3682/4885NPC1 3897/4885HTT 3329/4885 |
| US-20150051171-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | CBR3, CYCS, CBR1 | MAPT 4048/4885NPC1 3414/4885HTT 1000/4885 |
| US-20160272622-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | MT-CO1, UQCRB, MT-CO2 | MAPT 3682/4885NPC1 3897/4885HTT 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.